Edt.To
Edison Pharmaceuticals Inc. (EDT.TO) develops and commercializes prescription pharmaceutical products, primarily in the Canadian market, generating revenue through the sale of its drug portfolio.
Business. Edison Pharmaceuticals Inc. (EDT.TO) develops and commercializes prescription pharmaceutical products, primarily in the Canadian market, generating revenue through the sale of its drug portfolio.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Edison Pharmaceuticals Inc. (EDT.TO) develops and commercializes prescription pharmaceutical products, primarily in the Canadian market, generating revenue through the sale of its drug portfolio.
Edison Pharmaceuticals operates with a negative equity position of CAD -69.72 million and a debt-to-equity ratio of -0.3, indicating a capital structure heavily reliant on debt financing. The company’s liquidity is constrained, as evidenced by a current ratio of 0.08, suggesting limited short-term asset coverage over liabilities. Operating cash flow is negative at CAD -9.52 million, and free cash flow is also negative at CAD -47.63 million, reflecting ongoing cash outflows from operations.
Profitability metrics are severely underperforming relative to industry norms. The company reported a net loss of CAD -47.69 million and an operating loss of CAD -47.69 million, with a return on assets of -7.82% and a return on equity of 68.4% (due to negative equity base). These figures fall well below the typical profitability benchmarks for the pharmaceutical industry, which emphasize stable revenue and high gross margins.
Geographically, the company is concentrated in the Canadian market, with no disclosed international revenue segments. Its product portfolio is not segmented in the available data, but the company’s reliance on a single market increases exposure to local regulatory and economic shifts.
The company’s growth trajectory is negative, with no disclosed revenue growth in the most recent period. Analysts project a mean price target of CAD 3.15, with a median of CAD 3.15, indicating limited upside potential. The absence of positive revenue momentum and ongoing losses suggest a challenging outlook for near-term expansion.
Risk factors include high liquidity risk due to negative working capital and a negative net cash position after subtracting total debt. The company has a low dilution risk, with no near-term pressure from share issuance, and no dilution sources are disclosed in recent filings. However, the negative equity position and operating losses raise concerns about long-term solvency and the ability to service debt.
Recent events include the publication of the latest financial results, which show continued losses and negative cash flows. No material events such as mergers, acquisitions, or regulatory actions are disclosed in the available data.
- Edison Pharmaceuticals is operating at a loss with negative equity and free cash flow, indicating financial distress.
- The company’s liquidity is critically low, with a current ratio of 0.08 and negative net cash after debt.
- Analysts project limited upside, with a mean price target of CAD 3.15 and no positive recommendations.
- The company is geographically concentrated in Canada, increasing exposure to local market risks.
- No material growth drivers or positive operational trends are evident in the latest financial data.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,04 |
| Revenue | —no estimate | —no estimate | 5,0M CAD |
| Operating income | —no estimate | —no estimate | -9,1M CAD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- EDT.TO Market data — financials · 2026-05-27
- Spectral Medical Inc Market data — analyst estimates · 2026-05-27